RORγt agonist 2 is a novel agonist of RORγt with anticancer and immunomodulatory effects. It promotes the differentiation of Th17 cells and enhances the levels of pro-inflammatory cytokines, thereby increasing the cytotoxicity of lymphocytes. RORγt agonist 2 inhibits the production of regulatory T cells. It is extracted from patent WO2021136339A1, compound 17).

RORγt agonist 3 (extracted from patent WO2021136326A1, compound 23) is a novel agonist of RORγt with anticancer and immunomodulatory effects. It promotes the differentiation of Th17 cells and enhances the levels of pro-inflammatory cytokines, thereby increasing the cytotoxicity of lymphocytes. RORγt agonist 2 inhibits the production of regulatory T cells.

8-Phenyl-2,6-diethyl-BODIPY 505/515, derivative of BODIPY 505/515

Cloxacillin (HSDB-3042), a chlorinated derivative of Oxacillin, is a potent and orally bioactive antibacterial agent acting as a β-lactamase inhibitor with an IC50 of 0.04 µM. Cloxacillin can suppress the S. aureus-induced inflammatory response by inhibiting the activation of MAPKs, NF-кB and NLRP3-related protein.

AA-41612, antagonist of melanopsin-mediated phototransduction

Dammarenediol II, bioactive compound

Trehalose-6,6′-dibehenate, glycolipid

Sulfo-NHS-LC-LC-Biotin, biotin reagent

ODN-21595 is a novel Guanine-Modified TLR7 and TLR9 inhibitor that inhibits the release of IFN-α and IL-6 with no cytotoxicity. It has the potential for the treatment of systemic lupus erythematosus (SLE).

Nintedanib-d8, inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β